Michael B. Clearfield
Impact in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Surgery top 0.1%
- Lipoproteins and Cardiovascular Health
Papers in
- Surgery 39
- Lipoproteins and Cardiovascular Health 36
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 13
- Hormonal Regulation and Hypertension 3
- Co-authors
- Antonio Gotto (12 shared papers)John R. Downs (10 shared papers)Stephen E. Weis (11 shared papers)Polly A. Beere (7 shared papers)Deborah R. Shapiro (7 shared papers)Edwin J. Whitney (7 shared papers)Alexandra Langendörfer (6 shared papers)Paul M. Ridker (5 shared papers)
- Journals
- Current Atherosclerosis Reports (10 papers)The American Journal of Cardiology (6 papers)The Lancet (4 papers)Circulation (3 papers)Academic Medicine (2 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Michael B. Clearfield
68 papers receiving 13.0k citations
Michael B. Clearfield's Hit Papers
Peers
Comparison fields: 5 of 140
- Endocrinology, Diabetes and Metabolism 3.6k
- Surgery 7.6k
- Cardiology and Cardiovascular Medicine 2.4k
- Cancer Research 1.4k
- Immunology 1.3k
Countries citing papers authored by Michael B. Clearfield
This map shows the geographic impact of Michael B. Clearfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Clearfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Clearfield more than expected).
Fields of papers citing papers by Michael B. Clearfield
This network shows the impact of papers produced by Michael B. Clearfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Clearfield. The network helps show where Michael B. Clearfield may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael B. Clearfield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels Hit paper breakdown → | 1998 | 4342 |
| 2 | Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Hit paper breakdown → | 2010 | 1961 |
| 3 | Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events Hit paper breakdown → | 2001 | 1349 |
| 4 | Low-Dose Methotrexate for the Prevention of Atherosclerotic Events Hit paper breakdown → | 2018 | 1049 |
| 5 | Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events Hit paper breakdown → | 2001 | 689 |
| 6 | Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins Hit paper breakdown → | 2012 | 665 |
| 7 | Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials Hit paper breakdown → | 2019 | 604 |
| 8 | 2000 | 479 | |
| 9 | Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events Hit paper breakdown → | 2014 | 475 |
| 10 | 2004 | 445 | |
| 11 | 2013 | 316 | |
| 12 | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials Hit paper breakdown → | 2022 | 181 |
| 13 | 2013 | 173 | |
| 14 | 2015 | 132 | |
| 15 | C-reactive protein: a new risk assessment tool for cardiovascular disease. | 2005 | 130 |
| 16 | 2001 | 118 | |
| 17 | Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis Hit paper breakdown → | 2024 | 103 |
| 18 | 2001 | 84 | |
| 19 | 1997 | 72 | |
| 20 | 2006 | 69 |
About Michael B. Clearfield
Michael B. Clearfield is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism, Economics and Econometrics, Pharmacology and Cardiology and Cardiovascular Medicine, having authored 69 papers that have together received 14.0k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (36 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers), Adipokines, Inflammation, and Metabolic Diseases (4 papers), Hormonal Regulation and Hypertension (3 papers), Pharmacology and Obesity Treatment (3 papers), Cancer, Lipids, and Metabolism (3 papers) and Climate Change and Health Impacts (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (3.6k citations), Surgery (7.6k citations), Cardiology and Cardiovascular Medicine (2.4k citations), Cancer Research (1.4k citations) and Immunology (1.3k citations). Michael B. Clearfield has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Antonio Gotto, John R. Downs, Stephen E. Weis, Polly A. Beere, Deborah R. Shapiro, Edwin J. Whitney, Alexandra Langendörfer, Paul M. Ridker, Evan A. Stein and William B. Kruyer. Their work appears in journals such as Current Atherosclerosis Reports, The American Journal of Cardiology, The Lancet, Circulation and Academic Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.